[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmia-ventricular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmia-ventricular":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,80,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100626540","loop-recorder-implantation-in-patients-with-mitral-annular-disjunction-100626540",false,"NCT07436962","Loop Recorder Implantation in Patients With Mitral Annular Disjunction","ILR MAD IIT","Inclusion Criteria:\n\n* age between 18 and 60 years\n* patient not incapacitated\n* mitral annular disjunction confirmed by echocardiography\n* MR scan confirmed late-type gadolinium enhancement in the myocardium\n\nExclusion Criteria:\n\n* lack of informed consent\n* age under 18 years\n* limited capability\n* guardianship\n* active infection\n* cancer\n* previous ICD implantation\n* indication for ICD or ILR implantation based on current recommendation","ALL","18 Years","60 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of clinical trial is to prospectively collect data to investigate the prevalence of arrhythmia in young patients diagnosed with mitral annular disjunction who have no indication for implantable cardioverter defibrillator (ICD) or implantable loop recorder (ILR) implantation according to the current guideline. The study population is young (age 18-60), the participating patients have mitral annular disjunction confirmed by echocardiography and MR scan confirmed late-type gadolinium enhancement in the myocardium. This patient population has an increased risk of ventricular arrhythmias and sudden cardiac death. The investigators plan to implant 20 BioMonitor IIIm ILRs over a year in patients with mild or uncertain symptoms (dizziness, palpitations) and no malignant arrhythmias.\n\nAims of the study:\n\n1. Screening of asymptomatic patients with MAD for arrhythmia.\n2. In case of symptoms, to prove or exclude the underlying arrhythmia.\n\nBioMonitor IIIm ILR implantation is planned in the following patient population:\n\n1. Inclusion of 20 patients with mitral annular disjunction confirmed by echocardiography and late gadolinium enhancement in the myocardium by MRI.\n2. Only patients who do not meet the current indication for ICD or ILR implantation based on the current recommendation will be included in the study.",[27,28,29,30,31],"Mitral Annular Disjunction","Mitral Valve","Arrhythmia Ventricular","Sudden Cardiac Death Due to Cardiac Arrhythmia","Loop Recorder",[33,34,35,36,37,38],"mitral annular disjunction","MAD","sudden cardiac death","loop recorder","ventricular arrhythmia","mitral valve","RECRUITING","2026-02-27",{"date":42,"type":43},"2026-03-02","ACTUAL",{"date":45,"type":43},"2025-12-05",{"date":47,"type":21},"2030-02",{"name":49,"class":50},"Gottsegen National Cardiovascular Institute","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100608761","phase-4-adding-lidocaine-to-custodiol-mixture-100608761","NCT07205757","Adding Lidocaine to Custodiol Mixture","Adding Lidocaine to Custodiol® Cardioplegia to Decrease Post-bypass Ventricular Arrhythmias in Adult Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery; A Prospective Randomized Double-Blinded Clinical Trial.","Inclusion Criteria:\n\n* patients scheduled for elective Coronary artery bypass grafting surgery\n\nExclusion Criteria:\n\n* Emergency or Redo surgery.\n* Baseline rhythm other than sinus rhythm\n* Any degree of heart block, bundle branch block or hemiblock\n* Known allergy to lidocaine.\n* Chronic kidney disease.\n* Hepatic impairment.\n* Severe psychiatric illness.",{"count":60,"type":21},70,[62],"PHASE4","The Bretschneider solution, also known as Custodiol, has been widely used in open-heart surgery requiring cardiopulmonary bypass (CPB) since its introduction in 1970. Custodiol is widely favored by cardiac surgeons, being administered as a single dose, and is supposed to offer myocardial protection for up to three hours, permitting an uninterrupted surgical time, especially for intricate procedures The literature continues to debate the superiority of custodial and other cardioplegic solutions, such as the Del Nido and St. Thomas solutions, regarding both short-term and long-term outcomes. Clinical trials and daily practice showed that the use of custodial cardioplegic solution is associated with increased incidences of ventricular arrhythmias, and subsequently, the use of a defibrillator after Aortic Cross Clamp (ACC) removal at the end of CPB when compared to other types of cardioplegia solutions .One of the reasons for this difference mentioned in the literature is the lidocaine contained in other types of cardioplegic solutions. Lidocaine acts as a membrane stabilizer by blocking rapid sodium channels in the heart, thus preventing arrhythmias, in addition to its ability to inhibit calcium influx, which is the primary cause of ischemic-reperfusion injury.\n\nBased on these data, the investigators hypothesize that the increased incidence of Ventricular arrhythmias with the use of Custodiol compared to other solutions, such as St Thomas and Del Nido, may be attributed to the absence of lidocaine. Although Custodiol contains tryptophan as a membrane-stabilizing component, it may be beneficial to add lidocaine to the Custodiol mixture to decrease the incidence of VF after cross-clamp removal in adult patients undergoing elective CABG.",[65,29],"CAD",[67,68,69,70],"Custodiol","lidocaine","Bretschneider solution","Ventricular arrythmia","2025-11-14",{"date":73,"type":43},"2025-11-17",{"date":75,"type":43},"2025-10-03",{"date":77,"type":21},"2026-06-01",{"name":79,"class":50},"Fayoum University Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100589079","flecainide-in-idiopathic-premature-ventricular-contractions-and-related-cardiomyopathy-100589079","NCT06949748","Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy","UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy","UNIFLECA","Inclusion Criteria:\n\n* Frequent idiopathic PVCs (burden \\>5% on multiple 24-hour Holter ECG recordings)\n* Normal cardiac structure and function on echocardiography\n* No late gadolinium enhancement or myocardial scar on cardiac MRI\n* Normal coronary angiography (excluding ischemic cardiomyopathy)\n* Normal serum electrolytes and renal function\n* Willingness to comply with follow-up schedule and drug titration\n\nExclusion Criteria:\n\n* Structural heart disease\n* Ischemic heart disease (confirmed by angiography)\n* History of sustained ventricular arrhythmias\n* Left ventricular ejection fraction (LVEF) \\\u003C40% at baseline\n* Brugada syndrome, long QT syndrome, or other channelopathies\n* Contraindications to class IC agents\n* Use of concurrent antiarrhythmics or proarrhythmic drugs",true,{"count":90,"type":21},300,"OBSERVATIONAL","The UNIFLECA study is a prospective, single-arm, observational cohort evaluating the efficacy, safety, and tolerability of flecainide (in the form of Sanocard) in adults with frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy (PVCi-CMP). Frequent PVCs-defined as a burden \\>5% on two separate 24-hour Holter recordings-are increasingly recognized as a cause of reversible systolic dysfunction in patients without structural heart disease.\n\nParticipants undergo a comprehensive baseline evaluation including echocardiography, occasionally cardiac MRI, and coronary angiography or equivalent testing to confirm the absence of structural abnormalities. Patients are enrolled only if they are ineligible or unwilling to undergo catheter ablation, and have no contraindications to flecainide.\n\nFlecainide therapy is initiated at a starting dose of 100 mg\u002Fday and titrated up to 200 mg\u002Fday, guided by ECG findings, symptom response, and QRS duration. Regular follow-up occurs at three-month intervals over three years, with periodic 24-hour Holter monitoring and assessment of symptoms, LVEF, and adverse events.\n\nThe primary outcome is the reduction in PVC burden. Secondary outcomes include improvement in LVEF, symptom relief (measured by structured questionnaires), adverse effects, and long-term treatment adherence. The study aims to generate real-world data on the non-invasive management of PVCs with flecainide and explore its role as an alternative to ablation in carefully selected patients.",[94,95,96,29,97,98,99,100],"Premature Ventricular Beats","Premature Ventricular Complexes","Premature Ventricular Contraction (PVC)","Ventricular Dysfunction, Left","Ventricular Dysfunction","Cardiomyopathies, Secondary","Cardiomyopathies",[102,103,86,104,105,106,107,108],"Flecainide","Sanocard","PVC induced CMP","PVC","Premature Ventricular Contraction","Outflow Tract PVC","NonOutflow Tract PVC","2025-06-27",{"date":111,"type":43},"2025-07-02",{"date":113,"type":43},"2024-04-26",{"date":115,"type":21},"2027-12-01",{"name":117,"class":50},"University of Athens",6,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":51},"100558850","preventive-catheter-ablation-for-ventricular-arrhythmias-in-patients-with-end-stage-heart-failure-100558850","NCT06556485","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure rEfferred for Heart Transplantation eValuaTion (CASTLE-VT)","CASTLE-VT","Inclusion Criteria:\n\n1. Ischemic cardiomyopathy with left ventricular ejection fraction ≤ 35% (measured in the last 6 weeks prior to enrollment)\n2. Eligible for heart transplantation due to end-stage heart failure\n3. NYHA class ≥ III\n4. Impaired functional capacity or inability to exercise\n5. Indication for ICD therapy due to primary prevention\n6. Implanted ICD or ICD implantation within 3 months after randomization\n7. The patient is willing and able to comply with the protocol and has provided written informed consent\n8. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Previous catheter ablation for ventricular arrhythmias\n2. Previous appropriate ICD-therapy for ventricular arrhythmias\n3. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment\n4. Untreated hypothyroidism or hyperthyroidism\n5. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures during fertility age\n6. Mental or physical inability to participate in the study\n7. Listed as \"high urgent\" for heart transplantation\n8. Cardiac assist device implanted\n9. Planned cardiovascular intervention\n10. Life expectancy ≤ 12 month\n11. Uncontrolled hypertension\n12. Requirement for dialysis due to end-stage renal failure","99 Years",{"count":129,"type":21},160,[24],"CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study end points are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, Quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia\u002Fventricular fibrillation episodes, LV function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow up period of 2 years.",[133,134,135,136,137,138],"Heart Failure","Arrhythmia, Ventricular","Cardiomyopathy Ischemic","Catheter Ablation","Heart Transplantation","Left Ventricular Assist Device","2024-12-01",{"date":141,"type":43},"2024-12-04",{"date":143,"type":43},"2024-09-13",{"date":145,"type":21},"2027-01-01",{"name":147,"class":50},"Heart and Diabetes Center North-Rhine Westfalia"]